Apo-Si-K170A-C76

Phase 1Small molecule

IInterna Therapeutics Ltd.

Apo-Si-K170A-C76 is one of 14 small molecule programs targeting Systemic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SystemicActive, not recruiting

SystemicPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Systemic

#DrugCompanyPhaseTrials

Vivotif Typhoid Oral Vaccine

UUniversity of Maryland, Baltimore

Phase 3

1 2

Robitussin

Pfizer

Phase 1

1 3

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 4

Venclexta

AbbVie

Preclinical

1 5

Darzalex

Johnson & Johnson

Preclinical

1 6

Miochol

BBausch Health Americas, Inc.

Preclinical

1 7

Nipride

EExela Pharma Sciences, LLC.

Preclinical

1 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

1 9

Decadron

AAspen Global Incorporated

Preclinical

1 10

PIT565

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic1 trial

Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers

Active, not recruiting·IInterna Therapeutics Ltd.·Phase 1·NCT07095049·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Apo-Si-K170A-C76. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apo-Si-K170A-C76 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apo-Si-K170A-C76. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Interna Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInterna Therapeutics Ltd.

Apo-Si-K170A-C76

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Systemic1 trial

References

Drug Info

Quick Facts

Related News